Mr. Steven Brent Andrus, LCPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 125 Algonquin Dr, Rising Sun, MD 21911 Phone: 601-559-6337 |
Mrs. Bobbi-jo Gross-zell, LCPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 101 Colonial Way, Suite A, Rising Sun, MD 21911 Phone: 443-907-8245 |
Ms. Sarah Elizabeth John, LGPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 101 Colonial Way, Rising Sun, MD 21911 Phone: 717-881-6403 |
Laura Dahl, LCPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 1080 Joseph Biggs Memorial Hwy, Rising Sun, MD 21911 Phone: 436-937-1894 |
Joy Chester, LGPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 101 Colonial Way, Rising Sun, MD 21911 Phone: 443-907-8245 |
News Archive
In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphatic leukemia. This has awakened hopes that this analysis method could pave the way for important breakthroughs in immunotherapy research and treatment.
The weight loss industry in the United States is vast and generates about $20 billion each year from over 100 million dieters. Commercial weight loss programs design customer-focused program policies to shape and optimize satisfaction and development.
HIFU Prostate Services, LLC, a leading provider of minimally-invasive prostate cancer treatment using High Intensity Focused Ultrasound ("HIFU"), announces groundbreaking partnerships with Michael J. Lazar, MD in Santa Rosa, Calif. and John H. Jurige, MD in Louisville, Ky., to offer HIFU treatments for prostate cancer.
Researchers from UCLA's Jonsson Comprehensive Cancer Center led by Dr. Antoni Ribas, professor of medicine in the division of hematology-oncology, report preliminary results showing significant antitumor activity with very manageable side effects from a new drug being tested in patients with advanced melanoma, the deadliest form of skin cancer.
Scientists who recently identified the molecular start of Alzheimer's disease have used that finding to determine that it should be possible to forecast which type of dementia will develop over time - a form of personalized medicine for neurodegenerative diseases.
› Verified 7 days ago